This study evaluates the safety profile and effectiveness of adalimumab in Korean intestinal Behcet's disease (BD) patients in routine clinical practice.

Inclusion Criteria:

• Subjects must be an adult >= 19 years
• Subjects who are eligible to be treated with adalimumab for intestinal Behcet's disease in accordance with the approved label in Korea
• Subjects provide written authorization form for use/disclose of personal health data prior to participating in this study

Exclusion Criteria:

• Subjects who are contraindicated to any anti-TNF agent
• Female subjects who are pregnant or breast feeding
• Subjects who are participating in other interventional clinical trials

Intestinal Behcet's disease (BD) patients who are eligible to be prescribed adalimumab by the treating investigator as per Korean label will be enrolled.